Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

insmed inc. - INSM

INSM

Close Chg Chg %
177.42 0.46 0.26%

Closed Market

177.88

+0.46 (0.26%)

Volume: 1.04M

Last Updated:

Dec 26, 2025, 4:00 PM EDT

Trade Now

Company Overview: insmed inc. - INSM

INSM Key Data

Open

$178.90

 Day Range

176.67 - 179.44

52 Week Range

60.40 - 212.75

 Market Cap

$37.84B

Shares Outstanding

213.27M

 Public Float

210.36M

Beta

1.02

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$6.18

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

3.72M

  

INSM Performance

1 Week
 
 1.48%
 
1 Month
 
 -14.61%
 
3 Months
 
 29.48%
 
1 Year
 
 154.88%
 
5 Years
 
 401.04%
 

INSM Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 20
Full Ratings ➔

About insmed inc. - INSM

Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline. The company was founded in 1988 and is headquartered in Bridgewater, NJ.

INSM At a Glance

Insmed, Inc.
700 US Highway 202/206
Bridgewater, New Jersey 08807-3365
Phone 1-908-977-9900 Revenue 363.71M
Industry Pharmaceuticals: Major Net Income -913,772,000.00
Sector Health Technology 2024 Sales Growth 19.167%
Fiscal Year-end 12 / 2025 Employees 1,271
View SEC Filings

INSM Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 31.139
Price to Book Ratio 43.397
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -14.449
Enterprise Value to Sales 30.81
Total Debt to Enterprise Value 0.117

INSM Efficiency

Revenue/Employee 286,158.143
Income Per Employee -718,939.418
Receivables Turnover 6.993
Total Asset Turnover 0.217

INSM Liquidity

Current Ratio 5.45
Quick Ratio 5.119
Cash Ratio 4.819

INSM Profitability

Gross Margin 75.036
Operating Margin -216.265
Pretax Margin -250.219
Net Margin -251.238
Return on Assets -54.471
Return on Equity N/A
Return on Total Capital -57.129
Return on Invested Capital -70.305

INSM Capital Structure

Total Debt to Total Equity 460.483
Total Debt to Total Capital 82.158
Total Debt to Total Assets 64.887
Long-Term Debt to Equity 454.702
Long-Term Debt to Total Capital 81.127
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Insmed Inc. - INSM

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
188.46M 245.36M 305.21M 363.71M
Sales Growth
+14.63% +30.19% +24.39% +19.17%
Cost of Goods Sold (COGS) incl D&A
49.20M 60.18M 70.63M 90.79M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
27.85M 24.27M 10.58M 11.01M
Depreciation
22.80M 19.21M 5.53M 5.96M
Amortization of Intangibles
5.05M 5.05M 5.05M 5.05M
COGS Growth
+9.65% +22.31% +17.36% +28.56%
Gross Income
139.26M 185.18M 234.58M 272.91M
Gross Income Growth
+16.50% +32.98% +26.68% +16.34%
Gross Profit Margin
+73.89% +75.47% +76.86% +75.04%
2021 2022 2023 2024 5-year trend
SG&A Expense
506.42M 663.30M 915.51M 1.06B
Research & Development
272.74M 397.52M 571.01M 598.37M
Other SG&A
233.67M 265.78M 344.50M 461.12M
SGA Growth
+31.62% +30.98% +38.02% +15.73%
Other Operating Expense
- - - -
-
Unusual Expense
25.62M (19.28M) 28.38M 91.92M
EBIT after Unusual Expense
(392.78M) (458.85M) (709.31M) (878.49M)
Non Operating Income/Expense
(3.16M) 5.14M 43.99M 53.34M
Non-Operating Interest Income
174.00K 11.08M 42.13M 53.31M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
40.47M 26.45M 81.69M 84.91M
Interest Expense Growth
+36.90% -34.66% +208.91% +3.94%
Gross Interest Expense
40.47M 26.45M 81.69M 84.91M
Interest Capitalized
- - - -
-
Pretax Income
(436.41M) (480.15M) (747.01M) (910.07M)
Pretax Income Growth
-49.10% -10.02% -55.58% -21.83%
Pretax Margin
-231.57% -195.69% -244.76% -250.22%
Income Tax
(1.76M) 1.38M 2.56M 3.71M
Income Tax - Current - Domestic
104.00K 269.00K 378.00K 356.00K
Income Tax - Current - Foreign
1.58M 1.34M 2.23M 3.38M
Income Tax - Deferred - Domestic
(3.45M) (231.00K) (54.00K) (29.00K)
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(434.65M) (481.53M) (749.57M) (913.77M)
Minority Interest Expense
- - - -
-
Net Income
(434.65M) (481.53M) (749.57M) (913.77M)
Net Income Growth
-47.80% -10.79% -55.66% -21.91%
Net Margin Growth
-230.63% -196.26% -245.59% -251.24%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(434.65M) (481.53M) (749.57M) (913.77M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(434.65M) (481.53M) (749.57M) (913.77M)
EPS (Basic)
-3.877 -3.9138 -5.3375 -5.5703
EPS (Basic) Growth
-28.67% -0.95% -36.38% -4.36%
Basic Shares Outstanding
112.11M 123.03M 140.43M 164.04M
EPS (Diluted)
-3.877 -3.9138 -5.3375 -5.5703
EPS (Diluted) Growth
-28.67% -0.95% -36.38% -4.36%
Diluted Shares Outstanding
112.11M 123.03M 140.43M 164.04M
EBITDA
(339.31M) (453.86M) (670.35M) (775.56M)
EBITDA Growth
-38.41% -33.76% -47.70% -15.69%
EBITDA Margin
-180.04% -184.98% -219.64% -213.24%

Snapshot

Average Recommendation BUY Average Target Price 216.056
Number of Ratings 20 Current Quarters Estimate -1.28
FY Report Date 12 / 2025 Current Year's Estimate -6.043
Last Quarter’s Earnings -1.75 Median PE on CY Estimate N/A
Year Ago Earnings -5.57 Next Fiscal Year Estimate -3.414
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 18 9 20 20
Mean Estimate -1.28 -1.17 -6.04 -3.41
High Estimates -0.72 -0.68 -4.97 -1.78
Low Estimate -2.01 -1.63 -6.92 -5.36
Coefficient of Variance -23.34 -28.82 -6.98 -28.62

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 18 17 18
OVERWEIGHT 1 1 1
HOLD 1 1 1
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Insmed Inc. - INSM

Date Name Shares Transaction Value
Dec 4, 2025 Martina Flammer Chief Medical Officer 44,475 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Dec 4, 2025 Martina Flammer Chief Medical Officer 83,111 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $207.73 per share 17,264,648.03
Dec 4, 2025 Martina Flammer Chief Medical Officer 84,670 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $207.03 per share 17,529,230.10
Dec 4, 2025 Martina Flammer Chief Medical Officer 90,556 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $205.98 per share 18,652,724.88
Dec 4, 2025 Martina Flammer Chief Medical Officer 92,006 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $25.83 per share 2,376,514.98
Jul 10, 2025 Sara M. Bonstein Chief Financial Officer 12,023 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jul 10, 2025 Sara M. Bonstein Chief Financial Officer 141,781 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $26.46 per share 3,751,525.26
Jul 10, 2025 Sara M. Bonstein Chief Financial Officer 18,880 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jul 10, 2025 Sara M. Bonstein Chief Financial Officer 106,198 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $95.66 per share 10,158,900.68
Jul 10, 2025 Sara M. Bonstein Chief Financial Officer 104,499 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $24.7 per share 2,581,125.30
Jul 10, 2025 Sara M. Bonstein Chief Financial Officer 15,710 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jul 10, 2025 Sara M. Bonstein Chief Financial Officer 84,017 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $96.19 per share 8,081,595.23
Jul 10, 2025 Sara M. Bonstein Chief Financial Officer N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jul 10, 2025 Sara M. Bonstein Chief Financial Officer 128,064 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $26.43 per share 3,384,731.52
Jul 10, 2025 Sara M. Bonstein Chief Financial Officer 100,137 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $19.74 per share 1,976,704.38
May 20, 2025 Roger Adsett Chief Operating Officer 143,183 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 20, 2025 William H. Lewis Chair and CEO; Director 108,380 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 20, 2025 Michael A. Smith Chief Legal Officer 27,100 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 20, 2025 David Richard Brennan Director 126,933 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 20, 2025 David W. J. McGirr Director 103,973 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Insmed Inc. in the News